Guangdong Taienkang Pharmaceutical Co. Ltd (301263) - Net Assets
Based on the latest financial reports, Guangdong Taienkang Pharmaceutical Co. Ltd (301263) has net assets worth CN¥1.82 Billion CNY (≈ $266.03 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.51 Billion ≈ $367.06 Million USD) and total liabilities (CN¥690.44 Million ≈ $101.03 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Guangdong Taienkang Pharmaceutical Co. L (301263) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.82 Billion |
| % of Total Assets | 72.48% |
| Annual Growth Rate | 29.5% |
| 5-Year Change | 208.06% |
| 10-Year Change | N/A |
| Growth Volatility | 61.49 |
Guangdong Taienkang Pharmaceutical Co. Ltd - Net Assets Trend (2019–2024)
This chart illustrates how Guangdong Taienkang Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 301263 total assets for the complete picture of this company's asset base.
Annual Net Assets for Guangdong Taienkang Pharmaceutical Co. Ltd (2019–2024)
The table below shows the annual net assets of Guangdong Taienkang Pharmaceutical Co. Ltd from 2019 to 2024. For live valuation and market cap data, see 301263 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.82 Billion ≈ $265.79 Million |
-0.71% |
| 2023-12-31 | CN¥1.83 Billion ≈ $267.70 Million |
-1.33% |
| 2022-12-31 | CN¥1.85 Billion ≈ $271.29 Million |
+161.19% |
| 2021-12-31 | CN¥709.81 Million ≈ $103.87 Million |
+20.38% |
| 2020-12-31 | CN¥589.63 Million ≈ $86.28 Million |
+18.30% |
| 2019-12-31 | CN¥498.40 Million ≈ $72.93 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Guangdong Taienkang Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 135.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥387.32 Million | 21.92% |
| Other Components | CN¥1.38 Billion | 78.08% |
| Total Equity | CN¥1.77 Billion | 100.00% |
Guangdong Taienkang Pharmaceutical Co. Ltd Competitors by Market Cap
The table below lists competitors of Guangdong Taienkang Pharmaceutical Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SJW Group Common Stock
NYSE:SJW
|
$1.80 Billion |
|
Payoneer Global Inc
NASDAQ:PAYO
|
$1.80 Billion |
|
AECC Aero Science and Technology Co Ltd
SHG:600391
|
$1.80 Billion |
|
Guangdong Xinbao Electrical Appliances Holdings Co Ltd
SHE:002705
|
$1.80 Billion |
|
President Securities Corp
TW:2855
|
$1.80 Billion |
|
Shenzhen Mason Technologies Co Ltd
SHE:002654
|
$1.80 Billion |
|
BHP Group Limited
LSE:BHP
|
$1.80 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
$1.79 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangdong Taienkang Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,789,982,798 to 1,767,056,577, a change of -22,926,220 (-1.3%).
- Net income of 108,220,026 contributed positively to equity growth.
- Dividend payments of 135,121,410 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥108.22 Million | +6.12% |
| Dividends Paid | CN¥135.12 Million | -7.65% |
| Other Changes | CN¥3.98 Million | +0.22% |
| Total Change | CN¥- | -1.28% |
Book Value vs Market Value Analysis
This analysis compares Guangdong Taienkang Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.95x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 9.03x to 6.95x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥3.19 | CN¥28.85 | x |
| 2020-12-31 | CN¥1.85 | CN¥28.85 | x |
| 2021-12-31 | CN¥2.22 | CN¥28.85 | x |
| 2022-12-31 | CN¥4.36 | CN¥28.85 | x |
| 2023-12-31 | CN¥4.21 | CN¥28.85 | x |
| 2024-12-31 | CN¥4.15 | CN¥28.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangdong Taienkang Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.12%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.01%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.31x
- Recent ROE (6.12%) is below the historical average (13.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 11.06% | 11.06% | 0.73x | 1.37x | CN¥5.27 Million |
| 2020 | 27.27% | 22.68% | 0.85x | 1.42x | CN¥101.85 Million |
| 2021 | 16.91% | 18.37% | 0.69x | 1.33x | CN¥49.07 Million |
| 2022 | 9.42% | 22.29% | 0.38x | 1.10x | CN¥-10.80 Million |
| 2023 | 8.95% | 21.06% | 0.34x | 1.25x | CN¥-18.80 Million |
| 2024 | 6.12% | 15.01% | 0.31x | 1.31x | CN¥-68.49 Million |
Industry Comparison
This section compares Guangdong Taienkang Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangdong Taienkang Pharmaceutical Co. Ltd (301263) | CN¥1.82 Billion | 11.06% | 0.38x | $1.80 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Guangdong Taienkang Pharmaceutical Co. Ltd
Guangdong Taienkang Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers various products covering various therapeutic areas, including sexual health medicines, ophthalmic medicines, gastrointestinal medicines, Chinese patent medicines and external medicines, and sanitary materials in the… Read more